Management of direct-acting antiviral agent failures

Journal of Hepatology

Volumn 63, Issue 6, 2015, Pages 1511-1522

  Buti, Maria ^a,b   Riveiro Barciela, Mar ^a   Esteban, Rafael ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Daclatasvir; Direct acting antivirals; Hepatitis C virus; Interferon; Ledipasvir; Resistanceassociated variants; Simeprevir; Sofosbuvir; Treatment

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; DIRECT ACTING ANTIVIRAL AGENT; HEPACIVIRIN; HEPACIVIRIN INHIBITOR; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; ABT-267; ABT-333; ABT-450; ANILIDE; BENZIMIDAZOLE DERIVATIVE; BMS-790052; CARBAMIC ACID DERIVATIVE; FLUORENE DERIVATIVE; IMIDAZOLE DERIVATIVE; INTERFERON; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; MACROCYCLIC COMPOUND; PROTEINASE INHIBITOR; SULFONAMIDE; URACIL; URIDINE PHOSPHATE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER CIRRHOSIS; MUTATIONAL ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT VIRUS INFECTION; RETREATMENT; REVIEW; SEQUENCE ANALYSIS; TREATMENT OUTCOME; TURNOVER TIME; VIRUS LOAD; VIRUS MUTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; TREATMENT FAILURE; VIROLOGY;

ANILIDES; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CARBAMATES; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FLUORENES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INTERFERONS; MACROCYCLIC COMPOUNDS; PROTEASE INHIBITORS; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SULFONAMIDES; TREATMENT FAILURE; URACIL; URIDINE MONOPHOSPHATE;

EID: 84946945495     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.08.010     Document Type: Review

References (83)

1. K. Mohd Hanafiah, J. Groeger, A.D. Flaxman, and S.T. Wiersma Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 2013 1333 1342
2. J.P. Messina, I. Humphreys, A. Flaxman, A. Brown, G.S. Cooke, O.G. Pybus, and et al. Global distribution and prevalence of hepatitis C virus genotypes Hepatology 61 2015 77 87
3. S.S. Lim, T. Vos, A.D. Flaxman, G. Danaei, K. Shibuya, H. Adair-Rohani, and et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2224 2260
4. D.M. Jensen, J.G. O'Leary, P.J. Pockros, K.E. Sherman, P.Y. Kwo, M.E. Mailliard, and et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort Hepatology 60 2014 S219
5. B. Bacon, D. Dieterich, S. Flamm, K. Kowdley, E. Lawitz, S. Milligan, and et al. Efficacy of sofosbuvir and simeprevir-based regimens for 304 HCV treatment-experienced patients in a reallife setting; data from the TRIO network Hepatology 60 2014 S672
6. D. Dieterich, B. Bacon, S. Flamm, K. Kowdley, S. Milligan, N. Tsai, and et al. Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the TRIO network: academic and community treatment of a real-world, heterogeneous population J Hepatol 62 2015 S621
7. R. Reddy, J.K. Lim, A. Kuo, A.M. Di Bisceglie, H.E. Vargas, J.S. Galati, and et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-TARGET real world experience J Hepatol 62 2015 S193
8. P. Buggisch, C. Sarrazin, S. Mauss, H. Hinrichsen, K. Simon, J. Vermehren, and et al. Sofosbuvir-based treatment under real life conditions in Germany (The SOFGER trial) J Hepatol 62 2015 S622
9. M.S. Sulkowski, H.E. Vargas, A.M. Di Bisceglie, A. Kuo, K.R. Reddy, J.K. Lim, and et al. Safety and efficacy of sofosbuvir (SOF) in combination with simeprevir (SIM) + ribavirin (RBV) in patients with genotype 1: interim results of a prospective, observational study Hepatology 60 2014 S660
10. - J Hepatol 62 2015 S258
11. V. Saxena, F. Koraishy, M. Sise, J. Lim, R. Chung, A. Liapakis, and et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-word experience from HCV-TARGET J Hepatol 62 2015 S267
12. P. Buggisch, J. Petersen, K. Wursthorn, P. Atanasov, and A. Gauthier Real-world effectiveness of ledipasvir/sofosbuvir 8 weeks chronic hepatitis C treatment J Hepatol 62 2015 S280
13. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, S.C. Gordon, and et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
14. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, M.S. Sulkowski, and et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
15. S. Zeuzem, G.M. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, R.H. Hyland, and et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3 N Engl J Med 370 2014 1993 2001
16. G.R. Foster, S. Pianko, C. Cooper, A. Brown, D. Forton, R.G. Nahass, and et al. Sofosbuvir + PegInterferon/Ribavirin for 12 weeks vs Sofosbuvir + Ribavirin for 16 or 24 weeks in Genotype 3 HCV infected patients and treatment-experienced cirrhotic pacientes with genotype 2 HCV: the BOSON study J Hepatol 62 2015 S259 S260
17. C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, T. Goeser, and et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
18. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, R. Kauffman, and et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
19. J.G. McHutchison, M.P. Manns, A.J. Muir, N.A. Terrault, I.M. Jacobson, N.H. Afdhal, and et al. Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
20. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, S. Zeuzem, and et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
21. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, M.S. Sulkowski, and et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
22. P.Y. Kwo, E.J. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, D. Pound, and et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
23. M. Buti, K. Agarwal, Y. Horsmans, W. Sievert, E. Janczewska, S. Zeuzem, and et al. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C Gastroenterology 146 2014 744 753
24. M. Colombo, S. Strasser, C. Moreno, P. Abrao Ferreira, P. Urbanek, I. Fernandez, and et al. Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program J Hepatol 61 2014 976 983
25. I. Dierynck, A. Ghys, J. Witek, D. Luo, K. Janssen, B. Daems, and et al. Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study J Viral Hepatol 21 2014 835 842
26. T.L. Kieffer, S. De Meyer, D.J. Bartels, J.C. Sullivan, E.Z. Zhang, A. Tigges, and et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials PLoS One 7 2012 12
27. T.L. Kieffer, C. Sarrazin, J.S. Miller, M.W. Welker, N. Forestier, H.W. Reesink, and et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients Hepatology 46 2007 631 639
28. T. Kuntzen, J. Timm, A. Berical, N. Lennon, A.M. Berlin, S.K. Young, and et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients Hepatology 48 2008 1769 1778
29. R.A. Ogert, J.A. Howe, J.M. Vierling, P.Y. Kwo, E.J. Lawitz, J. McCone, and et al. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-alpha2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial Antivir Ther 18 2013 387 397
30. R.J. Barnard, J.A. Howe, R.A. Ogert, S. Zeuzem, F. Poordad, S.C. Gordon, and et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies Virology 444 2013 329 336
31. O. Lenz, T. Verbinnen, B. Fevery, L. Tambuyzer, L. Vijgen, M. Peeters, and et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies J Hepatol 28 2014 00881 00882
32. Verbinnen T, Fevery B, Vijgen L, Picchio G, De Meyer S, Lenz O. Phenotypic characterisation of genotype 1 hepatitis C NS3 protease variants from clinical studies with simeprevir. In: Presented at the international workshop on antiviral drug resistance, Berlin, Germany; 2014
33. I.M. Jacobson, G.J. Dore, G.R. Foster, M.W. Fried, M. Radu, V.V. Rafalsky, and et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial Lancet 384 2014 403 413
34. M. Manns, P. Marcellin, F. Poordad, E.S. de Araujo, M. Buti, Y. Horsmans, and et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 384 2014 414 426
35. C. Sarrazin, E. Lathouwers, M. Peeters, B. Daems, A. Buelens, J. Witek, and et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region Antiviral Res 116 2015 10 16
36. R.M. McCloskey, R.H. Liang, J.B. Joy, M. Krajden, J.S. Montaner, P.R. Harrigan, and et al. Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism J Infect Dis 211 2015 1288 1295
37. E. Lontok, P. Harrington, A. Howe, T. Kieffer, J. Lennerstrand, O. Lenz, and et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary Hepatology 2015 10.1002/hep.27934 [Epub ahead of print]
38. S. Susser, J.W. Wurzburg, S. Kofler, T.M. Welzel, D. Perner, S. Zeuzem, and et al. Long-term follow-up analysis of RAVs in HCV NS3, NS5A and NS5B in DAA therapy failure patients J Hepatol 62 2015 S679 S680
39. E. Lawitz, J.P. Lalezari, T. Hassanein, K.V. Kowdley, F.F. Poordad, A.M. Sheikh, and et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Lancet Infect Dis 13 2013 401 408
40. E. Lawitz, and E.J. Gane Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 369 2013 678 679
41. B.R. Bacon, D. Dieterich, S.L. Flamm, K.V. Kowdley, E. Lawitz, S. Milligan, and et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population Hepatology 60 2014 S672
42. E. Lawitz, M.S. Sulkowski, R. Ghalib, M. Rodriguez-Torres, Z.M. Younossi, A. Corregidor, and et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Lancet 384 2014 1756 1765
43. P. Kwo, N. Gitlin, R. Nahass, D. Bernstein, S. Rojter, E. Schiff, and et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1 J Hepatol 62 2015 S270
44. E. Lawitz, G. Matusow, E. DeJesus, E. Yoshida, F. Felizarta, R. Ghalib, and et al. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of Simeprevir (SMV) plus Sofosbuvir (SOF) in treatment-naïve or experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2 J Hepatol 62 2015 S264 S265
45. N. Afdhal, K.R. Reddy, D.R. Nelson, E. Lawitz, S.C. Gordon, E. Schiff, and et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 2014 1483 1493
46. N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin, M. Puoti, and et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
47. K.V. Kowdley, S.C. Gordon, K.R. Reddy, L. Rossaro, D.E. Bernstein, E. Lawitz, and et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
48. C. Sarrazin, H. Dvory-Sobol, E.S. Svarovskaia, B. Doehle, J.F. McCarville, P.S. Pang, and et al. baseline and post-baseline resistance analyses of phase 2/3 studies of ledipasvir/sofosbuvir ± RBV Hepatology 60 2014 1128A
49. K.R. Reddy, M. Bourliere, M. Sulkowski, M. Omata, S. Zeuzem, J.J. Feld, and et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis Hepatology 2015
50. S. Bagaglio, E. Messina, M. Merli, H. Hasson, A. Lazzarin, C. Uberti-Foppa, and et al. Analysis of natural resistance profile to NS5A replication complex inhibitors in different hepatitis C genotypes J Hepatol 62 2015 S658 S659
51. E. Svarovskaia, C. Hedskog, R. Martin, and D.M. Brainard Prevalence of pre-treatment NS5A and NS5B resistance associated variants and genetic variation within HCV subtypes across different countries J Hepatol 62 2015 S679
52. A.L. McCormick, L. Wang, A. Garcia-Diaz, M.J. Macartney, D.P. Webster, and T. Haque Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4 Antivir Ther 20 2015 81 85
53. J. Dietz, C. Berkowski, D. Perner, S. Susser, S. Zeuzem, and C. Sarrazin Consideration of viral resistance for optimization of direct antiviral therapy of chronic hepatitis C J Hepatol 62 2015 S681
54. H. Dvory-Sobol, D. Wyles, W. Ouyang, K. Chodavarapu, J. McNally, W. Cheng, and et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor Ledipasvir J Hepatol 62 2015 S221
55. E.S. Svarovskaia, H. Dvory-Sobol, B. Doehle, E.J. Gane, I.M. Jacobson, D.R. Nelson, and et al. L159F and V321A sofosbuvir treatment-emergent HCV NS5B substitutions Hepatology 60 2014 218A
56. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, I. Jacobson, and et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
57. D.L. Wyles, P. Ruane, M.S. Sulkowski, D. Dieterich, A.F. Luetkemeyer, T.R. Morgan, and et al. Daclatasvir plus Sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV coinfection: the ALLY-2 study J Hepatol 62 2015 S263
58. D.R. Nelson, J.N. Cooper, J.P. Lalezari, E. Lawitz, P.J. Pockros, N. Gitlin, and et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study Hepatology 61 2015 1127 1135
59. P. Andreone, M.G. Colombo, J.V. Enejosa, I. Koksal, P. Ferenci, A. Maieron, and et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection Gastroenterology 147 2014 e351
60. P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Y. Luo, C. Cooper, and et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV N Engl J Med 370 2014 1983 1992
61. J.J. Feld, K.V. Kowdley, E. Coakley, S. Sigal, D.R. Nelson, D. Crawford, and et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
62. F. Poordad, C. Hezode, R. Trinh, K.V. Kowdley, S. Zeuzem, K. Agarwal, and et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
63. P. Krishnan, R. Tripathi, G. Schnell, T. Reisch, J. Beyer, T. Dekhtyar, and et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with Paritaprevir/r-, Ombitasvir- and Dasabuvir-based regimens J Hepatol 62 2015 S220
64. P. Krishnan, J. Beyer, N. Mistry, G. Koev, T. Reisch, D. DeGoey, and et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A Antimicrob Agents Chemother 59 2015 979 987
65. E.F. Donaldson, P.R. Harrington, J.J. O'Rear, and L.K. Naeger Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir Hepatology 61 2015 56 65
66. E. Herrmann, A.U. Neumann, J.M. Schmidt, and S. Zeuzem Hepatitis C virus kinetics Antivir Ther 5 2000 85 90
67. J. Holland, K. Spindler, F. Horodyski, E. Grabau, S. Nichol, and S. VandePol Rapid evolution of RNA genomes Science (New York, NY) 215 1982 1577 1585
68. M. Martell, J.I. Esteban, J. Quer, J. Genesca, A. Weiner, R. Esteban, and et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution J Virol 66 1992 3225 3229
69. R. Bartenschlager, and V. Lohmann Replication of hepatitis C virus J Gen Virol 81 2000 1631 1648
70. J. Gregori, J.I. Esteban, M. Cubero, D. Garcia-Cehic, C. Perales, R. Casillas, and et al. Ultra-deep pyrosequencing (UDPS) data treatment to study amplicon HCV minor variants PLoS One 8 2013 e83361
71. J. Vermehren, and C. Sarrazin The role of resistance in HCV treatment Best Pract Res Clin Gastroenterol 26 2012 487 503
72. M. Vignuzzi, J.K. Stone, J.J. Arnold, C.E. Cameron, and R. Andino Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population Nature 439 2006 344 348
73. A. Thielen, N. Martini, B. Thiele, and M. Däumer Validation of HIV-1 drug resistance testing by deep sequencing: insights from comparative Sanger sequencing Antivir Ther 19 2014 A78
74. J.M. Pawlotsky Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014 Gastroenterology 148 2015 468 479
75. C. Sarrazin, H. Dvory-Sobol, E. Svarovskaia, B. Doehle, R. Martin, S. Zeuzem, and et al. The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV J Hepatol 62 2015 S620
76. S. Black, I. Pak, P. Ingravallo, P. McMonagle, R. Chase, M. Shaughnessy, and et al. Resistance analysis of virologic failures in hepatitis C genotype 1 infected patients treated with Grazoprevir/Elbasvir +/- Ribavirin: the C-WORTHY study J Hepatol 62 2015 S677 S678
77. M. Bourliere, J.P. Bronowicki, V. de Ledinghen, C. Hezode, F. Zoulim, P. Mathurin, and et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS) Lancet Infect Dis 15 2015 397 404
78. C. Hezode, H. Fontaine, C. Dorival, F. Zoulim, D. Larrey, V. Canva, and et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis Gastroenterology 147 2014 e134
79. X. Forns, S.C. Gordon, E. Zuckerman, E. Lawitz, J.L. Calleja, H. Hofer, and et al. Grazoprevir/Elbasvir plus Ribavirin For chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent J Hepatol 63 2015 564 572
80. D. Wyles, P. Pockros, G. Morelli, Z. Younes, E. Svarovskaia, J.C. Yang, and et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens Hepatology 61 2015 1793 1797
81. R. Esteban, L. Nyberg, J. Lalezari, L. Ni, B. Doehle, B. Kanwar, and et al. Successful retreatment with Sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior Sofosbuvir plus Ribavirin therapy J Hepatol 60 2014 S4 S5
82. E. Lawitz, S. Flamm, J.C. Yang, P.S. Pang, Y. Zhu, E. Svarovskaia, and et al. Retreatment fo patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks J Hepatol 62 2015 S192
83. Hezode C, Chevaliez S, Scoazec G, Soulier A, Bouvier-Alias M, Ruiz I, et al. Retreatment with an interferon-free combination of Simeprevir-Sofosbuvir in patients who had previously failed on HCV NS5A inhibitor based regimen. In: 13th European meeting on HIV & hepatitis - treatment strategies & antiviral drug resistance, Barcelona, Spain; 2015.